Eitel Tamara, Zeiner Kim Nikola, Assmus Katharina, Ackermann Hanns, Zoeller Nadja, Meissner Markus, Kaufmann Roland, Kippenberger Stefan, Valesky Eva Maria
Department of Dermatology, Venereology and Allergology, Goethe University Frankfurt, Frankfurt/Main, Germany.
Department of Biostatistics and Mathematical Models, Goethe University Frankfurt, Frankfurt/Main, Germany.
World Allergy Organ J. 2021 Apr 21;14(5):100536. doi: 10.1016/j.waojou.2021.100536. eCollection 2021 May.
An experienced life-threating anaphylactic reaction to hymenoptera venom can sustainably impair patients' quality of life (QoL). Besides carrying emergency medication, venom-specific immunotherapy (VIT) exists as a causal treatment of allergy.
This study aimed to examine QoL, anxiety, depression, and physical and mental health in patients allergic to hymenoptera venom before and during VIT and the impact of a tolerated sting challenge (SC).
Between July 2017 and August 2017, 142 patients with venom allergy were analyzed using validated questionnaires as the: Vespid Allergy Quality for Life Questionnaire" (VQLQ-d), the "Hospital Anxiety and Depression Scale" (HADS-D) and the "Short Form 36" (SF-36). To evaluate the impact of VIT and SC on the QoL, patients were divided into 3 groups: (A) VIT and tolerated SC (n = 45), (B) VIT before carrying out SC (n = 73), and (C) therapy-naïve before VIT (n = 20). Further parameters like gender, age, insect species, and severity of the anaphylactic reaction were assessed.
A significant correlation between the health-related QoL and the parameters of gender and state of treatment was seen. Especially male patients, as well as patients allergic to yellow jacket venom, benefit from a SC in terms of a significant increase in their QoL. In the total study cohort, a clear trend was observed towards a higher QoL in patients under VIT who tolerated a SC. Overall, neither the patients' age nor the insect species exerted a relevant influence on QoL, depression or anxiety. However, women showed a lower QoL combined with higher anxiety and depression scores than men.
Immunotherapy leads to an improved QoL, which can be further increased by a SC. A tolerated SC conceivably reassures the patients by objectifying the treatment success. Female patients appear to have a stronger impaired QoL per se. Taken together, a SC can be performed during VIT to strengthen the patients' QoL.
对膜翅目毒液发生过危及生命的过敏反应会持续损害患者的生活质量(QoL)。除了携带急救药物外,毒液特异性免疫疗法(VIT)是一种针对过敏的病因治疗方法。
本研究旨在调查膜翅目毒液过敏患者在VIT治疗前和治疗期间的生活质量、焦虑、抑郁以及身心健康状况,以及耐受的蛰刺激发试验(SC)的影响。
在2017年7月至2017年8月期间,使用经过验证的问卷对142名毒液过敏患者进行分析,这些问卷包括:“黄蜂过敏生活质量问卷”(VQLQ-d)、“医院焦虑抑郁量表”(HADS-D)和“简短健康调查问卷”(SF-36)。为了评估VIT和SC对生活质量的影响,将患者分为3组:(A)VIT和耐受SC组(n = 45),(B)进行SC前的VIT组(n = 73),以及(C)VIT治疗前未接受过治疗组(n = 20)。还评估了其他参数,如性别、年龄、昆虫种类和过敏反应的严重程度。
观察到与健康相关的生活质量与性别和治疗状态参数之间存在显著相关性。特别是男性患者以及对黄夹克毒液过敏的患者,在生活质量显著提高方面受益于SC。在整个研究队列中,观察到一个明显的趋势,即耐受SC的VIT治疗患者的生活质量更高。总体而言,患者的年龄和昆虫种类对生活质量、抑郁或焦虑均无相关影响。然而,女性的生活质量低于男性,同时焦虑和抑郁评分高于男性。
免疫疗法可改善生活质量,而SC可进一步提高生活质量。耐受的SC通过客观化治疗成功可能会使患者安心。女性患者本身的生活质量受损似乎更严重。综上所述,在VIT期间可进行SC以提高患者的生活质量。